A cohesive European policy for hepatitis B vaccination, are we there yet?

Clinical Microbiology and Infection

Volumn 20, Issue S5, 2014, Pages 19-24

  Lernout, T ^a,b   Hendrickx, G ^a,b   Vorsters, A ^a,b   Mosina, L ^c   Emiroglu, N ^b,c   Van Damme, P ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Viral Hepatitis Prevention Board   (Belgium)

^c WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

Author keywords

European region; Hepatitis B; Policy; Universal vaccination

Indexed keywords

HEPATITIS B VACCINE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DENMARK; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FINLAND; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; ICELAND; IMMIGRATION; IRELAND; NETHERLANDS; NORWAY; PRIORITY JOURNAL; REVIEW; SWEDEN; UNITED KINGDOM; VACCINATION; WORLD HEALTH ORGANIZATION; EUROPE; LEGISLATION AND JURISPRUDENCE; PREVENTIVE HEALTH SERVICE;

HEPATITIS B VIRUS;

COST-BENEFIT ANALYSIS; EUROPE; HEALTH POLICY; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 84897514131     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12535     Document Type: Review

References (38)

1. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. WHO, 2012. Available from: http://www.who.int/csr/disease/hepatitis/GHP_Framework_En.pdf.
2. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2013; 142: 270-286.
3. European Centre for Disease Prevention and Control. Hepatitis B and C surveillance in Europe. 2006-2011. ECDC, 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/Hepatitis-B-C-surveillance-report-2006-2011.pdf.
4. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53: 68-75.
5. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253: 197-201.
6. World Health Organization. Practices to improve coverage of the hepatitis B birth dose vaccine. WHO, 2013. Available from: http://apps.who.int/iris/bitstream/10665/78616/1/WHO_IVB_12.11_eng.pdf.
7. Yusuf HR, Daniels D, Smith PJ, Coronado V, Rodewald L. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA 2000; 284: 978-983.
8. Luman ET, Fiore AE, Strine TW, Barker LE. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage. JAMA 2004; 291: 2351-2358.
9. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J 2008 Oct; 27: 861-869.
10. Francois G, Hallauer J, Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine 2002; 21: 1-4.
11. Beeching NJ. Hepatitis B infections. BMJ 2004; 329: 1059-1060.
12. Rivas I, Martinez E, Sanvisens A et al. Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987-2006. Drug Alcohol Depend 2010; 110: 234-239.
13. Van Houdt R, Koedijk FD, Bruisten SM et al. Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: does it work? Vaccine 2009; 27: 3530-3535.
14. Alter MJ, Hadler SC, Margolis HS et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990; 263: 1218-1222.
15. Pollard AJ. Hepatitis B vaccination. BMJ 2007; 335: 950.
16. World Health Organization. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2010; 28: 589-590.
17. World Health Organization. Immunization surveillance, assessment and monitoring. Statistics on Hepatitis B. WHO, 2012. Accessed 20 August 2013. Available from: http://www.who.int/immunization_monitoring/diseases/HepB_coverage.jpg.
18. World Health Organization. Global Immunization Data. WHO, 2013. Available from: http://www.who.int/hpvcentre/Global_Immunization_Data.pdf.
19. World Health Organization. Centralized Information for Infectious Diseases (CISID). Vaccination coverage. WHO, 2011. Accessed 20 August 2013. Available from: http://data.euro.who.int/cisid/?TabID=319427.
20. UNICEF. Immunization summary. A statistical reference containing data through 2011. The 2013 edition. Available from: http://www.unicef.org/videoaudio/PDFs/EN-ImmSumm-2013.pdf.
21. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002; 67: 433-439.
22. World Health Organization. Vaccine-preventable diseases: monitoring system. 2013 global summary. Accessed 10 September 2013. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules?schedulecriteria%5Bregion%5D%5B%5D=EURO&schedulecriteria%5Bdummy%5D=&schedulecriteria%5Bvaccine%5D%5B%5D=HEPB&schedulecriteria%5BOK%5D=OK.
23. Mereckiene J, Cotter S, Lopalco P et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009? Vaccine 2010; 28: 4470-4477.
24. Euvac.Net. National Childhood Vaccinations Schedules. Accessed 10 September 2013. Available from: http://www.euvac.net/graphics/euvac/vaccination/vaccination.html.
25. Romano L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43(Suppl 1): S2-S7.
26. Boccalini S, Pellegrino E, Tiscione E et al. Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination. Hum Vaccin Immunother 2013; 9: 636-641.
27. Oviedo M, Munoz MP, Carmona G et al. The impact of immigration and vaccination in reducing the incidence of hepatitis B in Catalonia (Spain). BMC Public Health 2012; 12: 614.
28. Pitigoi D, Rafila A, Pistol A, Arama V, Molagic V, Streinu-Cercel A. Trends in hepatitis B incidence in Romania, 1989-2005. Euro Surveill 2008; 13: 70-73.
29. Iarovoi P, Rimis C, Spinu C, Isac M. Epidemiology of hepatitis B virus infection in the Republic of Moldova. J Infect Dev Ctries 2008; 2: 190-192.
30. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 2008; 18: 275-282.
31. Houweling H, Wittevrongel CF, Verweij M, Ruitenberg EJ. Public vaccination programmes against hepatitis B in The Netherlands: assessing whether a targeted or a universal approach is appropriate. Vaccine 2010; 28: 7723-7730.
32. Cowan SA. Denmark decides not to introduce hepatitis B into the childhood vaccination programme. Euro Surveill 2005; 10(E051103): 3.
33. Rimseliene G, Nilsen O, Klovstad H, Blystad H, Aavitsland P. Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992-2009. BMC Infect Dis 2011; 11: 153.
34. Borresen ML, Koch A, Biggar RJ et al. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health 2012; 102: 277-284.
35. Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011; 29: 466-475.
36. Viral Hepatitis Prevention Board. Burden and prevention of viral hepatitis in Arctic region. VHPB, 2013. Available from: http://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/vhv21n1.pdf.
37. Hepatitis B Expert Group. European orientation towards the better management of Hepatitis B. Recommendations of the Hepatitis B expert group. 2007. Available from: http://www.easl.eu/assets/application/files/45E788A6d01.pdf.
38. WHO Regional Office for the Western Pacific. Western Pacific Regional Plan for hepatitis B control through immunization. WHO, 2007. Available from: http://www.wpro.who.int/immunization/documents/docs/POA_HepB.pdf.